Characterizing IgG4-RD With 68Ga-FAPI PET/CT

Status Recruiting

Clinical Trial Summary

68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation,such as IgG4-related disease.And it might be more sensitive than FDG in detecting a certain type of inflammations according to our preliminary research.Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of IgG4-related disease.

Clinical Trial Description

Immunoglobulin G4-related disease (IgG4-RD) is an immune-mediated fibroinflammatory condition that is capable of affecting multiple organs. Common forms of presentation include:Type 1 (IgG4-related) autoimmune pancreatitis (AIP)，IgG4-related sclerosing cholangitis, major salivary gland enlargement or sclerosing sialadenitis; Orbital disease, often with proptosis and retroperitoneal fibrosis. The involved organs share a number of core pathologic features and striking clinical and serologic similarities, including tumor-like swelling of involved organs, a lymphoplasmacytic infiltrate enriched in IgG4-positive plasma cells, and a variable degree of fibrosis that has a characteristic "storiform" pattern. 68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and it might be a pan-tumor PET agent. Recently we have reported a case of IgG4-related disease revealed by 68Ga-FAPI and 18F-FDG PET/CT which showed FAPI was not more tumor-specific than FDG, furthermore,it might be more sensitive than FDG in detecting a certain type of inflammations-like the pancreatic lesion. Thus this prospective study is going to investigate whether 68Ga-FAPI PET/CT may be superior for diagnosis, therapy response assessment and follow-up of IgG4-related disease. ;

Study Design

Related Conditions & MeSH terms

IgG4-related Disease

Clinical Trial Details

NCT number	NCT04125511
Study type	Interventional
Source	Peking Union Medical College Hospital
Contact	Li Huo, M.D.
Phone	86-10-69155537
Email	huoli@pumch.cn
Status	Recruiting
Phase	Early Phase 1
Start date	November 1, 2019
Completion date	December 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03368274` - To Evaluate the Clinical Efficacy of Iguratimod in the Treatment of IgG4 Related Disease (IgG4-RD) With Mild Symptom	Phase 4
Not yet recruiting	`NCT03267875` - A Laboratory Scan of Patients With Aortic Aneurysms to IgG4 Levels in the Blood	N/A
Completed	`NCT02616705` - Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis
Completed	`NCT03669861` - Safety and Efficacy of Abatacept in IgG4-Related Disease	Phase 2
Recruiting	`NCT05625581` - Tofatib Treatment for IgG4-related Disease
Not yet recruiting	`NCT06285539` - Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases	Phase 2
Not yet recruiting	`NCT05746689` - Study of Sirolimus in IgG4-related Disease	N/A
Completed	`NCT03690908` - Infraorbital Nerve Involvement on Magnetic Resonance Imaging in IgG4-related Ophthalmic Disease
Completed	`NCT02899039` - Follicular Helper T Cells: Biological Marker and Involvement in the Physiopathology of the IgG4-related Disease	N/A
Recruiting	`NCT04660565` - Belimumab Treatment for IgG4-related Disease	Phase 4
Recruiting	`NCT01670695` - A Prospective Cohort Study of IgG4RD in China	N/A
Recruiting	`NCT03023371` - National Registry of IgG4-RD in China	N/A
Unknown status	`NCT01758393` - Glucocorticoids in Patients With IgG4-RD	Phase 2/Phase 3
Completed	`NCT02705638` - Treatment of IgG4-Related Disease With Revlimid and Rituximab	Phase 1
Recruiting	`NCT03473912` - Meir Medical Center Rheumatologic Biobank
Not yet recruiting	`NCT03466970` - Plasmablast Detection From IgG4-Related Disease Patients	N/A